Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
Takeda Pharmaceutical said on August 5 that the US FDA has approved its oral orexin receptor 2 (OX2R) agonist Orzeyful (oveporexton) for the treatment of adults with narcolepsy type 1 (NT1). Takeda views Orzeyful as one of its key future…
To read the full story
BUSINESS
- Argenx Steps Up Japan Hunt for Drug Discovery Seeds
October 7, 2026
- Asahi Kasei Therapeutics Reports Potential Data Breach Affecting 560,000
October 7, 2026
- Toho Files Objection to Court Block on Takeover Defense Move
October 7, 2026
- Keytruda Marks 3 Years at No. 1 in September: Encise
October 7, 2026
- Shionogi to Offload Allergy Drug Actair to Ceolia
October 7, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…